Archives

Louis Bourgeois, Johns Hopkins University, Baltimore Among the various experiences when visiting a developing country: there’s amazement at the sounds and the colour; delight at the warmth of th

Roy Gulick, Weill Cornell Medical College, New York Although the logic in antiretroviral HIV therapy has, for some years, been that two drugs are better than one; and three are better than two, this h

Timothy Wilkin Timothy Wilkin, Weill Cornell Medical College, New York A protease inhibitor, currently known as TMC114 has been tested in the POWER II study among some 300 patients who had failed mult

Thomas Cherpes Thomas Cherpes, University of Pittsburgh School of Medicine One thought provoking study at ICAAC explored the possible link between pelvic inflammatory disease, or PID, and herpes simpl

Matt Page Matt Page, United Biosource, MEDTAP Institute, Bethesda Vaccinating all age groups against influenza is likely to be cost effective – that’s acccording to a study presented at IC

Klaus Stohr Klaus Stohr, World Health Organisation, Geneva One of the keynote speeches in Washington described how avian influenza still looms large on the global health horizon. With the disease like

Bala Hota Bala Hota, Cook County Hospital, Chicago Researchers are now seeing growing numbers of MRSA infections in the community as well as in hospitals. One study presented at ICAAC was looking at p

Nick Lintzeris Nick Lintzeris of London’s Institute of Psychiatry A urine test which can distinguish between medicinally prescribed opiates and street heroin has been developed in London. France

Sandra Horning Abstract 349 Sandra Horning, Stanford University Medical Center It is not necessary to use rituximab along with standard CVP (cyclophosphamide, vincristine, predinsone) induction therap

Vincent Rajkumar Vincent Rajkumar, Divison of Hematology, Mayo Clinic At a section of the hematology meeting talking about newly diagnosed multiple myeloma and the evolving treatments, Vincent Rajkuma

Owen O’Connor Owen O’Connor, Memorial Sloan-Kettering Cancer Center, New York Owen O’Connor also gave data from early, two studies: one looking at treating lymphoma with the drug SAH

Dennis Slamon, UCLA School of Medicine, Los Angeles It may be reasonable to replace the anthracycline component of adjuvant chemotherapy with carboplatin in HER-2 positive patients with early breast c

Reporting from: – 2005 Multidisciplinary Prostate Cancer Symposium, February 17-19, Hyatt Grand Cypress, Orlando, Florida In this edition: Will they or won’t they relapse? For patients wit

Reporting from: ECCO-13 The European Cancer Conference, Paris, October 30–November 3, 2005 In this edition: Martine Piccart gave the Paris ECCO conference her group’s latest data from the

Primary angioplasty after a myocardial infarction is also better than thrombolysis in a real world setting: though up to two hours after the infarction the two methods are equivalent, according to Swe

The ABT578-eluting ENDEAVOR stent has been compared head-to-head with sirolimus-eluting Cypher. Duke University’s David Kandzari told us more. [audio:https://www.audiomedica.com/podcasting/aha20

John McMurray The VALIANT trial compared ACE-inhibitor, ARB and a combination of the two in high-risk post-MI patients, and found there may be an interaction between them and statins. John McMurray fr

Jeffrey Berger A study of 9 000 women with established cardiovascular disease has found that mortality is reduced by 25 per cent among those taking aspirin, and that the dose of daily aspirin does not

Registry analysis suggests women often receive too much treatment with glycoprotein 2B3A inhibitors. Duke University’s Karen Alexander told us more. [audio:https://www.audiomedica.com/podcasting

David Brown The effect of aspirin in preventing cerebrovascular disease is different in women as compared with men. A meta-analysis of six studies presented at the AHA meeting by David Brown shows tha

In addition to lipid levels, statins are known to have anti-inflammatory, anti-thrombotic and immunomodulatory effects which could help explain their impact on cardiovascular outcomes. But do these pl

Terje Pedersen More evidence for the benefits of aggressive lipid-lowering with statins has come from the IDEAL study, which randomised nearly 9000 post-MI patients to either 80 mg of atorvastatin or

A 20 000-person study of eicosapentaenoic acid supplements gave solid scientific support for EPA use to prevent cardiovascular events among patients with established coronary artery disease. Mitsuhiro

For atrial fibrillation, oral anti-coagulation remains the treatment of choice despite the potential of an anti-platelet regimen based on aspirin and clopidogrel, according to the ACTIVE-W trial. Stua

Todd McAllister Blood vessels made through tissue engineering are being trialled in humans and may provide a future source of grafts from coronary applications. That is the latest from a California-ba